An observational study in Phthalate Exposure, Preeclampsia and Estrogen, sponsored by Second Affiliated Hospital of Wenzhou Medical University. Completed at 1 site in China. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.
Sponsored by Second Affiliated Hospital of Wenzhou Medical University · Observational
Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes. There is increasing evidence concerning the potential endocrine disrupting for phthalate exposure during pregnancy. Prenatal exposure phthalates would disrupt the level of sex hormone in pregnant women, which results in preeclampsia. The relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human beings was often sex-specific associations. Because of the potentially harmful influence of prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure during pregnancy.
882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.
This study's enrollment of 60 is below the median of 163 across 380 observational studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Second Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 133 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The participants include pregnant women meeting the inclusion criteria.
Exclusion Criteria:
pregnant woman without any disease of pregnancy
Other: test Phthalates, estrogen and progesterone
pregnant woman with preeclampia but without any other disease of pregnancy
Other: test Phthalates, estrogen and progesterone
test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
Phthalates in urine
Collect the urine of pregnant women and test the abundance of Phthalates
Time frame: 37 weeks to 40 weeks gestation
The female progesterone
Collect the placenta tissue of pregnant women and test the abundance of estrogen progesterone receptor
Time frame: 37 weeks to 40 weeks gestation
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital of Wenzhou Medical University